The US FDA has recently approved Johnson and Johnson’s Acuvue- Abiliti overnight therapeutic lenses for the management of myopia. The orthokeratology (ortho-k) contact lens is developed by Johnson & Johnson Vision, a part of the Johnson & Johnson medical devices companies.
Myopia or nearsightedness is a chronic and progressive disease. Young children that are less than 12 years of age and become myopic are the most vulnerable to develop high myopia and can be at increased risk of sight-threatening eye diseases later in life.
Abiliti overnight ortho-k contact lenses are specifically designed and fitted to match the eye based on their unique corneal shape to temporarily reshape the cornea. Abiliti Overnight will be available in two different contact lens designs: Abiliti overnight therapeutic lenses, and Abiliti overnight therapeutic lenses for astigmatism.
Abiliti overnight contact lenses are optimised by the use of corneal topography, refractive error and other measurements connected to an innovative fitting software. The software is a sophisticated and user-friendly tool that provides a precise measure of the corneal shape and accurately guides the eye care professional through the fitting process for consistent and successful first fit rates of approximately 90%.
The Abiliti Overnight therapeutic lenses for myopia management have been shown to reduce the axial elongation of the eye in myopic children by 0.28mm, on average, over a 2-year period.